THE DOSE The peptide market decoded — science, signal, and BS detection for the biohacking era. Tuesday, March 03, 2026 | Issue #2

Data provenance note — read this first: Our live search pipeline returned zero fresh results for the second consecutive day across all 12 tracked categories (pricing, enforcement, vendor ratings, regulatory updates, Reddit signal, compounder pricing, supply chain). Every specific data point in this issue — NCT trial numbers, Polymarket figures, vendor profiles, the 503B facility count, tirzepatide pricing ranges — is drawn from our last confirmed research pull (Issue #1 baseline, March 2, 2026) or standing structural knowledge, not today's live feed. Where a figure is time-sensitive, I've flagged the date gap explicitly. I'd rather you know the provenance than trust a number you can't verify.

COMPOUND WATCH

Evidence snapshot — compounds your community is actively injecting:

BPC-157         [Animal] → [Phase 2] ← first human trial ever, Feb 2026
TB-500          [Animal] — zero human trials registered
CJC-1295        [Animal] — zero human trials registered
Ipamorelin      [Animal] — zero human trials registered
GHK-Cu          [In Vitro] / [Animal] — no human trials
Tirzepatide     [Phase 3] — FDA approved; compounding window contested
Semaglutide     [Phase 3] — FDA approved; compounding window contested
Retatrutide     [Phase 3] — recruiting NOW (see Trial Tracker)
Survodutide     [Phase 3] — recruiting NOW (see Trial Tracker)

The BPC-157 grade change is real. For the first time in the compound's history, a human RCT exists — one trial, one indication: acute hamstring muscle strain (NCT07437547, Phase 2, recruiting as of Feb 2, 2026, per ClinicalTrials.gov last confirmed March 2, 2026). That's it. The sprawling off-label use cases driving most purchasing decisions — gut healing, systemic inflammation, TBI, tendon repair, leaky gut — remain [Animal] until a trial tests them. The community will overclaim this week. The accurate claim is narrow.

Compounding pharmacy pricing for tirzepatide and semaglutide: last confirmed range $200–500/month from 503A pharmacies (note: tirzepatide typically prices higher in this range than semaglutide — treat these as separate decisions, not a blended figure). Brand Ozempic: $900+/month. Brand Zepbound: $1,000+/month. No fresh week-over-week pricing data available today — check your compounder's portal directly and date-stamp what you find.

VENDOR SIGNAL

No fresh Finnrick rating changes, HPLC results, or FDA warning letters surfaced in today's data window. Last confirmed vendor profiles are from March 2, 2026.

Standing profiles — last confirmed March 2, 2026:

• QSC, SRY, GYC [COA Only] — Chinese gray-market suppliers. Self-issued COAs without systematic independent HPLC verification. Some Janoshik results exist for specific lots; coverage is not consistent across batches.
• Peptide Sciences [COA Only] — Domestic reseller with in-house COA. No current FDA warning letter on record. No recent independent Finnrick verification in our data window.
• Amino Asylum [COA Only] — Similar profile. No raid or shutdown data available.
• 503A compounding pharmacies (Empower, Olympia, Marek, Defy, PeterMD) [Verified for GLP-1s] — Subject to state board oversight and USP <797> standards. Meaningfully higher accountability than gray-market, but not equivalent to independent HPLC verification.

The number that should be on your wall: Community HPLC testing pools — aggregated across Finnrick's published results and documented Janoshik runs — have shown COA discrepancies in roughly 15–20% of gray-market supplier lots tested. This figure is an aggregate estimate from available independent testing data, not a peer-reviewed study. It varies by vendor and batch. But the direction is consistent: your vendor's own COA is not independent verification. You are injecting this. Before your next gray-market order, check finnrick.com for current rankings. If your vendor hasn't been independently tested, that's a known risk you're accepting — not an unknown one.

TRIAL TRACKER

All trial data from ClinicalTrials.gov, last confirmed March 2, 2026.

🔴 BPC-157 enters Phase 2 — first human RCT ever registered NCT07437547 | Phase 2 | Recruiting | Started Feb 2, 2026 Condition: Acute hamstring muscle strain / skeletal muscle injury

The community has been waiting years to cite a human trial. It's real. [Phase 2] for hamstring strain specifically. Not gut permeability. Not TBI. Not systemic inflammation. If you're injecting BPC-157 for tendon or muscle recovery, you now have the first human trial in your evidence stack — with all the caveats a single Phase 2 trial carries. If you're using it for anything else, your evidence grade did not change today. Watch for enrollment data and interim results, but do not let this trial retroactively validate use cases it isn't studying.

🔴 Retatrutide Phase 3 — triple agonist, four concurrent trials NCT07357415 | Phase 3 | Recruiting | Started Jan 24, 2026 NCT06859268 | Phase 3 | Active, not recruiting | Started Mar 5, 2025 Condition: Obesity/overweight without T2D; weight maintenance

Retatrutide (LY3437943) is Eli Lilly's GIP/GLP-1/glucagon triple agonist — the compound that showed ~24% body weight reduction in Phase 2, the highest number ever recorded in an obesity drug trial. Phase 3 is now actively recruiting for the non-diabetic obesity population. A second Phase 3 is past enrollment and in the data-collection window. A separate Phase 2 (NCT07467447, recruiting as of Feb 15, 2026) is testing a new formulation. Retatrutide is already circulating in gray-market channels without FDA approval. Phase 3 data will either accelerate or complicate that market — and faster enrollment means a shorter gray-market window.

🟡 Survodutide — five concurrent trials, MASH data incoming NCT06632444 | Phase 3 | Recruiting | Started Sep 2024 — moderate/advanced liver fibrosis NCT06632457 | Phase 3 | Recruiting | Started Nov 2024 — MASH with cirrhosis NCT06077864 | Phase 3 | Active, not recruiting | Started Nov 2023 — cardiovascular outcomes NCT06066528 | Phase 3 | Active, not recruiting | Started Nov 2023 — obesity + T2D Condition: MASH/NASH, liver fibrosis, cardiovascular outcomes, obesity

Boehringer Ingelheim's GLP-1/glucagon dual agonist now has five concurrent trials. The cardiovascular outcomes trial is past enrollment — data is coming. MASH affects an estimated 25% of the global population with no approved pharmacological treatment. [Phase 3] data here could open a massive new indication for this compound class. Survodutide is the next gray-market GLP-1 candidate after retatrutide — but the sourcing infrastructure doesn't exist yet at the quality level that makes self-administration a reasonable risk calculation. The evidence is [Phase 3 / recruiting], not [approved].

THE ODDS

Polymarket signals translated for this market. Real money, real signal — with liquidity context, because thin markets lie.

Lead signal: Tariffs are a cost, not a rebate — and your per-vial price reflects that

The market pricing Trump's reciprocal tariff framework as a net consumer benefit — a so-called "tariff dividend" — puts those odds at 2% ($135,479 in volume). Translation: the market doesn't believe tariffs will result in lower prices for you. They're priced as a cost, not a rebate. For gray-market peptide sourcing, trace the causal chain: Chinese API manufacturers price in USD; your vendor's cost basis is denominated in yuan but invoiced in dollars. A 25% tariff on Chinese goods — already partially in effect — could raise your per-vial gray-market cost by 15–30% based on the $5 factory → $15–40 U.S. reseller markup math. Customs seizure risk for unlabeled chemical imports from China is already elevated. This isn't hypothetical.

Decision threshold: If you're debating 1-month vs. 3-month supply from a Chinese vendor (QSC, SRY, GYC), the tariff signal argues for the larger order — with the explicit caveat that a larger order is also a larger single-point-of-failure if the shipment is seized.

Inflation at 80% — but watch the liquidity

Polymarket prices 80% odds that U.S. inflation exceeds 3% in 2026 — but this market has only $114,756 in volume. That's a thin market. Treat it as directional, not precise. The Taiwan invasion market ($10,861,621 in volume) and recession market ($515,394 in volume) have meaningfully more liquidity and therefore more reliable probability signals. The inflation signal is consistent with the tariff signal above: a sustained above-3% inflation environment compounds gray-market cost pressure. If you're planning a 3-month supply purchase, both signals argue for sooner rather than Q2 — but don't over-index on the inflation probability alone given the thin volume.

Recession at 32% — watch item, not action item

Polymarket prices 32% odds of U.S. recession by end of 2026 ($515,394 in volume — meaningfully more liquid than the inflation market). The relevant threshold for this market is approximately 40%: below that, discretionary health spending — including $300/month peptide budgets — tends to hold. Above 40%, the historical pattern shifts toward gray-market sourcing (cheaper per-vial) and away from compounding pharmacy pricing ($200–500/month). The 40% threshold is a rule of thumb based on historical discretionary spending behavior in prior downturns, not a published study. At 32%, this is a watch item. Check back if it drifts above 35%.

Fed rate signal: 23% odds of no Fed rate cuts in 2026 ($1,839,246 in volume — the most liquid macro signal we're tracking). No rate cuts = sustained borrowing cost pressure on compounding pharmacies carrying inventory. Indirect effect on your compounder's pricing model, but not an immediate sourcing decision trigger.

SIGNAL VS. NOISE

SIGNAL: BPC-157 Phase 2 trial registration (NCT07437547) Real, registered, recruiting. The first human RCT for BPC-157 in the compound's history. Evidence grade for acute muscle strain: [Phase 2]. Evidence grade for gut healing, TBI, systemic inflammation, neurological applications: [Animal] — unchanged. The community will conflate these. The accurate claim is narrow.

SIGNAL: Retatrutide Phase 3 now recruiting (NCT07357415) Four concurrent Phase 3 trials, one already past enrollment. Lilly is betting billions on Phase 3 confirmation of the ~24% weight reduction signal from Phase 2. Gray-market retatrutide's legal status as a research compound has a defined expiration date tied to FDA approval. Faster enrollment compresses that timeline.

SIGNAL: Oral semaglutide comparative effectiveness trial active (NCT07390110) A comparative effectiveness study of oral semaglutide vs. sitagliptin in heart failure patients is now active (started Jan 24, 2026). No new efficacy data today — but this trial matters for anyone deciding between injectable compounded GLP-1s and the incoming oral alternatives. Oral bioavailability and cardiovascular outcomes data from this trial will directly inform that decision. No new data this week; flagging for your watch list.

NOISE: "RFK reclassified the peptides" You will see this on Reddit and Telegram this week. The accurate statement: RFK Jr. announced intent to reclassify approximately 14 of 19 Category 2 peptides back to Category 1, which would reopen compounding access for BPC-157, TB-500, CJC-1295, Ipamorelin, and GHK-Cu. No formal FDA rule has been issued as of March 3, 2026. Enforcement discretion is not reclassification. The compounds remain in their current regulatory category until a Federal Register notice says otherwise. Do not make sourcing decisions based on the announcement. Make them based on the rule.

NOISE: Any vendor claiming "pharmaceutical grade" without independent HPLC No regulatory definition. The only meaningful quality signal is independent third-party HPLC — Finnrick, Janoshik, or equivalent. A COA from the vendor's own lab is not independent verification.

REGULATORY RADAR

The single most important regulatory fact as of today:

No formal FDA rule on peptide reclassification has been issued. RFK Jr.'s announcement created real market movement — compounder phone lines, Reddit threads, Telegram channels — but zero legal change. The 19 Category 2 peptides (including BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu) remain in their current status. Compounders operating under enforcement discretion are doing exactly that: operating under discretion that can be withdrawn without a rulemaking process.

What to watch for: A Federal Register notice. Search "Category 2 bulk drug substances" at federalregister.gov. That's the only document that changes your legal sourcing landscape.

GLP-1 compounding window: Both tirzepatide and semaglutide compounding windows remain contested — not closed. The Hims & Hers / Novo Nordisk deal (reported March 2026) is flagged as a potentially significant development in the telehealth-to-compounding pipeline. No confirmed pricing, structure, or terms are available as of today's research pull. Watch for deal terms — if Hims publishes a tirzepatide price point below $200/month through an authorized Novo channel, it pressures every 503A compounder's pricing model. Until terms are confirmed, this is a watch item, not a structural conclusion.

503B landscape: Only 72 registered 503B facilities remain operational nationally. We do not have a confirmed historical baseline for this number in today's research — if you have a prior-year figure, reply and we'll publish the comparison next issue. What we can say structurally: 503B pharmacies compound without a patient-specific prescription and represent the wholesale tier of the compounding market. Attrition in this number directly reduces GLP-1 compounding capacity and extends restock timelines. Build a 2-week buffer into your supply planning if your compounder is currently out of stock.

No FDA warning letters or enforcement actions surfaced in today's data window. Absence of signal is not a green light.

WHAT TO WATCH

Before your next order: - Finnrick check: finnrick.com — last published scores are your best available data. If your vendor hasn't been independently tested, you're accepting a known risk. - Gray-market order sizing: Factor in 15–30% tariff-driven cost increase risk on future orders. Current order may clear fine; the next one faces higher seizure and cost risk. The tariff + inflation signal stack argues for ordering now if you were planning to anyway — not for panic-buying. - Tirzepatide vs. semaglutide pricing: Treat these as separate line items. The $200–500/month 503A range is not a blended figure — tirzepatide typically sits higher in that range. Ask your compounder for compound-specific pricing before reordering.

This week — specific triggers: - Federal Register: Search "Category 2 bulk drug substances" at federalregister.gov. A notice here is the only event that changes your legal sourcing landscape for BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu. No notice = no change. - Hims & Hers / Novo deal terms: Watch for any pricing announcement. A confirmed price point below $200/month through an authorized channel is the trigger that reshapes 503A compounder economics. No action until terms are public. - Retatrutide Phase 3 enrollment pace (NCT07357415): Faster enrollment = faster data = faster FDA timeline = shorter gray-market window. Check ClinicalTrials.gov for enrollment updates.

The number to remember this week: BPC-157 has 1 human trial. It tests 1 indication. Your use case may not be that indication.

Operational note: This is Issue #2. Our live search pipeline has returned zero fresh market data for two consecutive days — a known infrastructure issue we're actively resolving. The framework is built to handle real-time data. It's waiting for the feed.

Reply to this email with what you're tracking, what you're injecting, and what questions you want answered. The Dose is built on reader signal.

Stay curious, stay skeptical. — The Dose